Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.41 |
| ▸ | CSGALNACT1 | Q8TDX6 | 10/20 | 0.40 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.38 |
| ▸ | SDCBP | O00560 | 1/20 | 0.37 |
| ▸ | SDC2 | P34741 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180234 | 1.00 | ADAMTS4 (0.41) | ADAMTS4CSGALNACT1GPR139DGAT1BRD4 | |
| SCHEMBL12872573 | 0.93 | GPR139 (0.38) | ADAMTS4GPR139BRD4CYP17A1ELANE | |
| SCHEMBL12872574 | 0.91 | CYP17A1 (0.40) | ADAMTS4GPR139BRD4CYP17A1ELANE | |
| SCHEMBL1179762 | 0.85 | BRD9 (0.44) | GPR139BRD4CYP17A1 | |
| SCHEMBL1180113 | 0.84 | MAPT (0.48) | CSGALNACT1DGAT1L3MBTL1 | |
| SCHEMBL1180109 | 0.84 | MAPT (0.48) | CSGALNACT1DGAT1L3MBTL1 | |
| SCHEMBL12872713 | 0.82 | CSGALNACT1 (0.60) | CSGALNACT1DGAT1 | |
| SCHEMBL1180372 | 0.82 | MEN1 (0.46) | CSGALNACT1DGAT1 | |
| SCHEMBL1180367 | 0.82 | MEN1 (0.46) | CSGALNACT1DGAT1 | |
| SCHEMBL1180305 | 0.82 | MMP1 (0.40) | CSGALNACT1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324241-B2 | Triazolo compounds useful as DGAT1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110034468-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | BRISTOL-MEYERS SQUIBB COMPANY | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034468-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | ADAMTS4 2516/4885CSGALNACT1 617/4885GPR139 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.